The FDA Cleared Senseonics' Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System For People With Type 1 And Type 2 Diabetes Aged 18 Years And Older, Eversense 365 Is The World's First One Year CGM System
Portfolio Pulse from Benzinga Newsdesk
The FDA has cleared Senseonics' Eversense 365, a next-generation continuous glucose monitoring system for people with diabetes. This system is the first of its kind to offer a one-year duration for continuous monitoring.
September 17, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Senseonics received FDA clearance for its Eversense 365 CGM system, marking a significant milestone as it is the first one-year continuous glucose monitoring system available. This approval could enhance Senseonics' market position and drive revenue growth.
The FDA clearance of the Eversense 365 system is a major regulatory milestone for Senseonics, likely to positively impact its stock price. The product's unique one-year monitoring capability could attract more users, enhancing market share and revenue.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100